search
Back to results

The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis

Primary Purpose

Tuberculosis, Spinal

Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Isoniazid
Rifampicin
Ethambutol
Pyrazinamide
Sponsored by
Beijing Chest Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tuberculosis, Spinal focused on measuring tuberculosis, spinal, general, operation, drug, therapy

Eligibility Criteria

15 Years - 75 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients are diagnosed as spinal tuberculosis clinically,and they do not receive antituberculosis therapy or with 2 weeks.
  • The age is between 15 years old and 75 years old.
  • Patients have good compliance,and have clear surgical indications.4.Willing to join the research

Exclusion Criteria:

  • Patients have surgical contraindications.
  • Patients have bad habits:taking drug,drinking.3.Patients have mental disease.
  • Patients have bad compliance.
  • Patients have hematogenous disseminated pulmonary tuberculosis, serious central nervous system tuberculosis,and serious extrapulmonary tuberculosis.
  • Patients with drug resistance for Antituberculosis drugs,and patient have to change the treat plan,and patients have immunodeficiency diseases.
  • Patients are not diagnosed as spinal tuberculosis clearly.
  • Not willing to join the research

Sites / Locations

  • Beijing chest hospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

anti-tuberculosis treatment two weeks

anti-tuberculosis treatment four weeks

Arm Description

anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for two weeks.

anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for four weeks.

Outcomes

Primary Outcome Measures

Vertebral side width of soft tissue is measured by CT after operation.

Secondary Outcome Measures

Amount of bone trabecula between bone graft surfaces is measured by X-ray after operation.

Full Information

First Posted
May 23, 2015
Last Updated
June 22, 2015
Sponsor
Beijing Chest Hospital
Collaborators
Beijing Municipal Science & Technology Commission
search

1. Study Identification

Unique Protocol Identification Number
NCT02477852
Brief Title
The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis
Official Title
The Study of Standardized Preoperative Anti-tuberculosis Treatment of Surgical Treatment of Spinal Tuberculosis Patients
Study Type
Interventional

2. Study Status

Record Verification Date
June 2015
Overall Recruitment Status
Unknown status
Study Start Date
April 2015 (undefined)
Primary Completion Date
December 2017 (Anticipated)
Study Completion Date
December 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beijing Chest Hospital
Collaborators
Beijing Municipal Science & Technology Commission

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine the better preoperative anti-tuberculosis treatment period of patients with spinal tuberculosis.
Detailed Description
Quality assurance plan:All the investigators will receive uniform training. Standard cases follow-up,collection,management systems will be established.The process of cases follow-up,collection,management will be supervised by the third party.Data entry will be in the manner of independent parallel entry.The endpoints events are judged by third party.Statistical analysis are implemented by the statistics institutions of the third party.In order to control the bias,this study takes multicenter,random,control study design. Sample size assessment:Under the condition of multicenter,random,control design, computational formula takes the rate comparisons of two groups.The key endpoints event is soft tissue width of vertebral side measured by computed tomography. The incidence of the key endpoints event in two weeks group is 30%.The incidence of the key endpoints event in four weeks group is 15%.When alpha value is 0.5 and power value is 0.9,the sample size is 161 patients.If loses visit rate is 20%,the sample size is 194 patients. Statistical analysis plan:The key events are analyzed by chi-squared test.The statistical significance factors among them are calculated by relative risk. Data checks and source data verification are supervised by a third-party organization (contract research organization,CRO). Standard Operating Procedures:Investigator's brochure has explained in detail about the standard operating procedures of everything.Data dictionary can be found in standard operating procedures. Plan for missing data: The investigators Set a 20% rate of lost to follow-up.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tuberculosis, Spinal
Keywords
tuberculosis, spinal, general, operation, drug, therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
anti-tuberculosis treatment two weeks
Arm Type
Experimental
Arm Description
anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for two weeks.
Arm Title
anti-tuberculosis treatment four weeks
Arm Type
Experimental
Arm Description
anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for four weeks.
Intervention Type
Drug
Intervention Name(s)
Isoniazid
Intervention Description
preoperative treatment of spinal tuberculosis with Isoniazid
Intervention Type
Drug
Intervention Name(s)
Rifampicin
Intervention Description
preoperative treatment of spinal tuberculosis with Rifampicin
Intervention Type
Drug
Intervention Name(s)
Ethambutol
Intervention Description
preoperative treatment of spinal tuberculosis with Ethambutol
Intervention Type
Drug
Intervention Name(s)
Pyrazinamide
Intervention Description
preoperative treatment of spinal tuberculosis with Pyrazinamide
Primary Outcome Measure Information:
Title
Vertebral side width of soft tissue is measured by CT after operation.
Time Frame
up to 3 months
Secondary Outcome Measure Information:
Title
Amount of bone trabecula between bone graft surfaces is measured by X-ray after operation.
Time Frame
up to 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients are diagnosed as spinal tuberculosis clinically,and they do not receive antituberculosis therapy or with 2 weeks. The age is between 15 years old and 75 years old. Patients have good compliance,and have clear surgical indications.4.Willing to join the research Exclusion Criteria: Patients have surgical contraindications. Patients have bad habits:taking drug,drinking.3.Patients have mental disease. Patients have bad compliance. Patients have hematogenous disseminated pulmonary tuberculosis, serious central nervous system tuberculosis,and serious extrapulmonary tuberculosis. Patients with drug resistance for Antituberculosis drugs,and patient have to change the treat plan,and patients have immunodeficiency diseases. Patients are not diagnosed as spinal tuberculosis clearly. Not willing to join the research
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
shibing qin, doctor
Phone
86+10+13581557856
Email
ly13785361227@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
shi bi qin, doctor
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
shao fa xu, doctor
Organizational Affiliation
Beijing Chest Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Beijing chest hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
101149
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
shibing qin, doctor

12. IPD Sharing Statement

Learn more about this trial

The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis

We'll reach out to this number within 24 hrs